Khurram Jamil

Khurram Jamil is a seasoned medical professional with extensive experience in clinical development and regulatory strategy. As Chief Medical Officer at Galectin Therapeutics since January 2024, Khurram manages the NAVIGATE Phase 2b/3 trial for Belapectin in NASH cirrhosis patients and oversees regulatory interactions with the FDA. Previously, Khurram held the position of Vice President of Hepatology at Mallinckrodt Pharmaceuticals from January 2015 to February 2024, leading the Terlipressin program and successfully securing its approval. Khurram's earlier roles include Executive Director focusing on clinical development across various therapeutic areas at Mallinckrodt, Senior Medical Director at IKARIA, Inc., where the approval of Terlipressin in Australia was achieved, and Clinical Research Scientist at Organon Pharmaceuticals, managing clinical trials in CNS and anesthesia. Khurram Jamil earned an MD from Seton Hall University and completed a research fellowship at New York University.